Influence of zoledronic acid and pamidronate on tooth eruption in children with osteogenesis imperfecta

• Published in: Bone (New York, N.Y.) Vol. 182; p. 117069
• Main Authors: Del Rio Cantero, Natalia, Mourelle Martínez, María Rosa, Sagastizabal Cardelús, Belén, De Nova García, Joaquín Manuel
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2024
• Subjects: Animals; Bisphosphonates; Bone Density; Bone Density Conservation Agents - adverse effects; Child; Dental eruption; Diphosphonates - adverse effects; Humans; Longitudinal Studies; Osteogenesis imperfecta; Osteogenesis Imperfecta - complications; Osteogenesis Imperfecta - drug therapy; Pamidronate; Pamidronate - therapeutic use; Tooth Eruption; Zoledronic acid; Zoledronic Acid - therapeutic use; Dental eruption; Osteogenesis imperfecta; Zoledronic acid; Pamidronate; Bisphosphonates
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/j.bone.2024.117069

Osteogenesis imperfecta (OI) is a congenital disease comprising a heterogeneous group of inherited connective tissue disorders. The main treatment in children is bisphosphonate therapy. Previous animal studies have shown that bisphosphonates delay tooth eruption. The aim of this study is to determine whether patients with OI treated with pamidronate and/or zoledronic acid have a delayed eruption age compared to a control group of healthy children. An ambispective longitudinal cohort study evaluating the age of eruption of the first stage mixed dentition in a group of children with OI (n = 37) all treated with intravenous bisphosphonates compared with a group of healthy children (n = 89). Within the study group, the correlation (Pearson correlation test) between the type of medication administered (pamidronate and/or zoledronic acid) and the chronology of tooth eruption is established, as well as the relationship between the amount of cumulative dose received and tooth eruption. The age of eruption of the study group was significantly delayed compared to the age of eruption of the control group for molars and lateral incisors (p < 0.05). Patients who received higher cumulative doses had a delayed eruption age compared to those with lower cumulative doses (p < 0.05). There is a high positive correlation between age of delayed tooth eruption and Zoledronic acid administration. Patients with OI have a delayed eruption of the 1st stage mixed dentition compared to a control group of healthy children. This delayed eruption is directly related to the cumulative dose of bisphosphonates and the administration of zoledronic ac. •Osteogenesis imperfecta patients treated with bisphosphonates present delayed eruption•The delayed eruption is directly related to the accumulated dose of bisphosphonates.•Zoledronic acid is more related to delayed eruption than pamidronate.